Comprehensive Genomic Profiling, in record time. Accurate. Clinically Proven. Fast.
|
|
- Brent Lawrence
- 5 years ago
- Views:
Transcription
1 Comprehensive Genomic Profiling, in record time Accurate. ly Proven. Fast.
2 PCDx advantages Comprehensive genomic profiling, in record time PCDx Comprehensive Genomic Profiling (CGP) provides precise information about the targetable cancer pathways in the tumor to allow for more effective clinical decision-making. Comprehensive genomic profiling on small tissue specimens With only 1/3 rd of the sample failure rate of other leading providers 3, Paradigm s success rate in profiling tumors with PCDx is 94%. 4 Through our proprietary library creation methods and other laboratory techniques that provide us with an average depth of coverage of >5x, we obtain comprehensive genomic profiling results on small tissue specimens with limited tumor (e.g. 5-1%), including fine needle aspirates (FNAs). Data on ~29 sequential samples submitted for PCDx Challenges presented by current CGP solutions Obtaining quality results on small tissue specimens A large percentage of tumor biopsies that are received by molecular laboratories have either a limited amount of tissue (e.g. FNAs) or low tumor cellularity (e.g. samples with 5-1% tumor). These present practical challenges when attempting to run comprehensive genomic testing for many patients unless an accurate test such as PCDx is run. Rapid turnaround time Advanced stage cancer patients typically progress rapidly. Often these patients are unable to obtain their next course of therapy due to worsening of condition. 1,2 There is a clinical need to obtain your testing results as fast as possible. ly meaningful results Tissue should be tested to maximize potential treatment options. A large number of reports are generated citing either unactionable genomic findings or inapplicable clinical trials. This creates practical challenges and frustration to the treating clinician when deciding what to do next ,723 Fastest turnaround time 123 PCDx Cases Run and Reported with insufficient DNA and mrna 52 PCDx cases cancelled prior to testing due to insufficient tissue 94% Sample Success Rate Paradigm delivers clinical results to our clients in 4 to 5 business days from receipt of the tissue sample. Our laboratory processes have been engineered to ensure a reduced time to next therapy and continuity of clinical care. Day 1 Sample is received and pathology confirms initial diagnosis with H&E. Successful PCDx Runs Day 2 Tumor DNA & RNA are extracted, purified and quantified. 175 Samples Insufficient for Testing Day 3 DNA & RNA library creation. Day 4 Sequencing and analysis. Day 5 interpretation of results, quality assurance performed and clinical report delivered. 1. Von Hoff, D. D., et al., Pilot study using molecular profiling of patients tumors to find potential targets and select treatments for their refractory cancers. Journal of Oncology, (21) 28(33), , 3. Kalyan C. Mantripragada, et al., Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a n-national Cancer Institute Designated Cancer Program. Journal of Oncology Practice (216) 12:4, e396-e44. 4, 6. Paradigm s sample rejection rate is approximately ~6% vs. 18% as seen for other leading platforms (Matripragada et al. Journal of Oncology Practice. 216). Paradigm internal data set and analysis on first 27 patients run on the PCDx platform where only 175 patients had insufficient tissue for analysis.
3 ly proven & actionable Paradigm PCDx is a comprehensive genomic profiling (CGP) test that interrogates the key drivers of cancer: DNA, RNA and. s Changes in the DNA sequence, including insertions, deletions and base substitutions. Somatic mutation analysis has become standard of practice for solid tumors in order to identify therapeutic sensitizing and resistance mutations (e.g., EGFR, KRAS, BRAF). Test Description: Test Name: Paradigm Cancer Diagnostic (PCDx) Carcinoma of Unknown Primary Tumor Diagnosis: Collection Site: Right Supraclavicular region Specimen Type: Block Case/Specimen ID: Specimen Collected: Specimen Received: Next-Generation Sequencing () assays analyzing mutations, copy number variations, messenger RNA levels and select protein expression by Immunohistochemistry () as may be requested, all tied to levels of evidence relative to an associated treatment. BRAF Actionable EGFR (ERBB1) HRAS KRAS NRAS PIK3CA Ver: PCDx Copy Number Variation Gene Fusions HER2 (ERBB2) Actionable ROS1 amphiregulin (AREG) Actionable CDA ERBB3 epiregulin (EREG) VEGFR2 (KDR) MET TUBB3 TS (TYMS) TUBB3 AR Negative TS (TYMS) ROS1 hent1 (SLC29A1) Negative MGMT TOP1 Changes in the protein expression as measured by have been utilized for many years as the gold-standard to quantitate the actual translation of altered gene products. Our ability to interrogate key protein markers (e.g. PD-L1, HER2, AR, MGMT, TOP1) provides insights on potential response to hormonal manipulations, cytotoxic, targeted, and immuno-oncology agents as well as emerging clinical trials. On Compendia Driven Strategies Irinotecan TOP1 3+ 5% Yes Yes Off Compendia Driven Strategies Ceritinib Crizotinib Gene Fusion ROS1 Ado-trastuzumab emtansine Lapatinib Pertuzumab Trastuzumab CNV HER2 (ERBB2) Cetuximab Panitumumab BRAF HRAS Cetuximab of : L1 = 1 / LII-1 = II-1 / = II-2 / = II-3 / Gene expression is the process by which information from a gene is used in the synthesis of a functional protein. Sequencing-based mrna expression analysis enables the significant multiplexing of biomarker targets (e.g., ER, ERCC1). LIII = III / = Different Tumor Type 445 N. Fifth Street, Suite 3 Paradigm Diagnostics, Inc CLIA# 3D Phoenix, AZ Report Date: 4/7/ of 12 Sample Patient 7 1/1/1974 Sample Report Sample Doctor Sample Cancer Center Test Name: Paradigm Cancer Diagnostic (PCDx) Tumor Diagnosis: Breast Cancer - Invasive Collection Site: Left Breast Specimen Type: Block Case/Specimen ID: Specimen Collected: Specimen Received: Test Description: Next-Generation Sequencing () assays analyzing mutations, copy number variations, messenger RNA levels and select protein expression by Immunohistochemistry () as may be requested, all tied to levels of evidence relative to an associated treatment. Specimen Image: PIK3CA c.1633g>a p.e545k Actionable BRCA1 BRCA2 ER (ESR1) CCND1 Actionable HER2 (ERBB2) Ver: PCDx amphiregulin (AREG) Actionable BCL-2 survivin (BIRC5) BRCA1 IGF1R SSTR2 TOPO IIa TUBB3 AR t Changed HER2 (ERBB2) t Changed ER (ESR1) t Changed PR (PGR) t Changed AR Actionable CA IX Negative hent1 (SLC29A1) PDL1 TILs Negative PDL1 Tumor PTEN TOP1 TP (TYMP) TRKpan Negative TP (TYMP) 2+ 3% Letrozole RNA BCL x Bevacizumab Doxorubicin Epirubicin CA IX Negative + 1% hent1 2+ 8% Doxorubicin Epirubicin Gemcitabine TOPO IIa % 5.3 % PFS > 1.3 PFS > 1.3 Patients treated with genomically guided therapy had a superior median PFS compared to those treated with non-genomically guided therapy (86 days vs. 49 days, p=.5, H.R.=.55, 95% C.I.: ). PCDx provides associations for the most drug therapies. PCDx associates with >8 single agent drugs and combination therapies including: Standard Chemotherapies Hormonal Therapies RNA Capecitabine % 43.2 % Somatic rearrangements are usually result in the formation of a fusion gene, derived from two disrupted normal genes, from which a fusion transcript and protein is generated. (e.g., EML4-ALK) On Compendia Driven Strategies 4 4 Genomically Genomically n-genomically n-genomically Pathologist H&E was performed and the percent tumor available for analysis was 95% Patient's Select Cancer Genomic & Proteomic Landscape Copy Number Variation p <.1 p < Rearrangements & Gene Fusions Patient Name: Patient DOB: PCDx Case#: Ordering Physician: Ordering Location: Proportion of Patients Achieving a PFS Ratio > 1.3 Proportion of Patients Achieving a PFS Ratio > 1.3 CNVs are alterations of the DNA of the cancer genome that result in the cell having abnormal copies of one or more sections of the DNA. These alterations can have a significant impact on response to therapy (e.g., HER2). Pathologist H&E was performed and the percent tumor available for analysis was 9 Specimen Image: Patient's Select Cancer Genomic & Proteomic Landscape Copy Number Variations In an independent clinical study, genomically directed therapy guided by Paradigm PCDx improved progression free survival as compared to non-genomically guided therapy.5 Percent Percent of Patients of Patients Sample Patient 12 1/1/1911 Sample Report Sample Doctor Sample Cancer Center Patient Name: Patient DOB: PCDx Case#: Ordering Physician: Ordering Location: Supported by published clinical data 29.6x Targeted Agents (TKIs and MABs) Immunotherapies s. Off Compendia Driven Strategies Sorafenib + carboplatin, paclitaxel of : L1 = 1 / LII-1 = II-1 / = II-2 CNV CCND1 / = II-3 / Paradigm Diagnostics, Inc CLIA# 3D N/A LIII = III / = Different Tumor Type 445 N. Fifth Street, Suite 3 Phoenix, AZ Report Date: 8/31/ of 11 5, 7. R adovich, M., et al., benefit of a precision medicine based approach for guiding treatment of refractory cancers. Oncotarget, (216) 7(35),
4 PCDx can help identify the best cancer treatment options for you today. Start getting better results, faster. Accurate. 5x average depth of coverage Low sample rejection (QNS) rates (6% vs. 18%)6 ly Proven. Analyzes Tumor DNA, RNA & Prospective data published showing improvement in Progression Free Survival (PFS)7 Provides associations to >8 single agent and combination therapies Full PCDx results possible from >5% tumor; including FNAs Fast. delivered in 4 to 5 business days Reduces time to next therapy Ensures continuity of clinical care For more information, please contact Client Services at or visit paradigmdx.com
5 Paradigm Diagnostics, Inc. 445 N. 5th Street, Suite 3 Phoenix, AZ paradigmdx.com
StrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient
StrandAdvantage Tissue-Specific Cancer Genomic Tests Empowering Crucial First-Line Therapy Decisions for Your Patient Harness the power of precision medicine with StrandAdvantage Precision medicine in
More informationNew Drug development and Personalized Therapy in The Era of Molecular Medicine
New Drug development and Personalized Therapy in The Era of Molecular Medicine Ramesh K. Ramanathan MD Virginia G. Piper Cancer Center Translational Genomics Research Institute Scottsdale, AZ Clinical
More informationGPS Cancer. The Era of Complete Genomics and Proteomics is Here. Advanced molecular profiling to inform personalized treatment strategies
MOLECULAR PROFILING GPS Cancer The Era of Complete Genomics and Proteomics is Here Advanced molecular profiling to inform personalized treatment strategies www.nanthealth.com What information do you need
More informationBreast Cancer RESULT INTERPRETATION THERAPRINT OVERVIEW
Breast Cancer PAGE 1 OF 7 Patient: DOB: Patient #: Gender: Customer Ref.: SPECIMEN Requisition: Collection Date: Date Received: Report Date: Specimen Site: Tumor Origin: Unspecified Breast PHYSICIAN Ordering
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
More informationPRECISION INSIGHTS. Liquid GPS. Blood-based tumor profiling and quantitative monitoring. Reveal more with cfdna + cfrna.
PRECISION INSIGHTS Liquid GPS Blood-based tumor profiling and quantitative monitoring Reveal more with cfdna + cfrna www.nanthealth.com Why Blood-Based Tumor Profiling? Although tissue-based molecular
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationRefining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis
5/17/13 Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis Johannes Kratz, MD Post-doctoral Fellow, Thoracic Oncology Laboratory
More informationIndividualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy
Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy 1 st st International Oncological Conference Wrocław, October 6 th, 2012 Dr. Frank Kischkel Individualized Cancer Therapy:
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationPersonalized Genetics
Personalized Genetics Understanding Your Genetic Test Results Tracey Evans, MD September 29, 2017 Genetics 101 Punnett Square Genetic Pedigree 2 Genetics 101 Punnett Square Genetic Pedigree 3 It s not
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationPersonalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients
Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs
More informationPersonalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader
Personalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader Agenda PHC Approach Provides Better Patient Outcome FMI offers Comprehensive Genomic Profiling,
More informationTreatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
More informationImplementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges
Implementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges Frédérique Nowak - 21 october 2015 "Putting Science into Standards event:
More informationLooking Beyond the Standard-of- Care : The Clinical Trial Option
1 Looking Beyond the Standard-of- Care : The Clinical Trial Option Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor
More informationIncorporating Genomic Science into the Community Oncology Setting
Incorporating Genomic Science into the Community Oncology Setting Moderator: Carla Balch, President, NantCare Panelists: Robert Green, M.D., M.S.C.E., Senior Vice President, Clinical Oncology, Flatiron
More informationIndividualized therapy in lung cancer Where are we in 2012?
UNIVERSITY OF OF TORINO DEPARTMENT OF ONCOLOGY Individualized therapy in lung cancer Where are we in 2012? Giorgio V. Scagliotti University of Torino Professor of Medical Oncology Department of Oncology
More informationSlide 1. Slide 2. Slide 3. Individualized Therapy in Lung Cancer : Where are we in 2011? Notable Advances in Cancer Research in the last 2 years
Slide 1 Individualized Therapy in Lung Cancer : Where are we in 2011? Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it Slide 2 Notable
More informationMETASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationLiquid biopsy: the experience of real life case studies
Liquid biopsy: the experience of real life case studies 10 th September 2018 Beatriz Bellosillo Servicio de Anatomía Patológica Hospital del Mar, Barcelona Agenda Introduction Experience in colorectal
More informationMP Circulating Tumor DNA Management of Non-Small-Cell Lung Cancer (Liquid Biopsy)
Medical Policy BCBSA Ref. Policy: 2.04.143 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Medicine Related Policies 2.04.121 Miscellaneous Genetic and Molecular Diagnostic Tests 2.04.45 Molecular
More informationCirculating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy)
Circulating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy) Policy Number: 2.04.143 Last Review: 1/2019 Origination: 1/2018 Next Review: 1/2020 Policy Blue Cross and Blue Shield
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationClinical Grade Genomic Profiling: The Time Has Come
Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation
More informationNew Developments in the Treatment of Colorectal Cancer. Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre
New Developments in the Treatment of Colorectal Cancer Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre Personalized Medicine Currently already part of oncology:
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationCDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018
CDx in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900 Research unit Versailles Saint-Quentin-en-Yvelines
More informationDisclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
More informationIdentification of Potential Therapeutic Targets by Molecular and Genomic Profiling of 628 Cases of Uterine Serous Carcinoma
Identification of Potential Therapeutic Targets by Molecular and Genomic Profiling of 628 Cases of Uterine Serous Carcinoma Nathaniel L Jones 1, Joanne Xiu 2, Sandeep K. Reddy 2, Ana I. Tergas 1, William
More informationOverview of Biomarker Development for Immune PD-1/L1 Checkpoint Blockade
Overview of Biomarker Development for Immune PD-1/L1 Checkpoint Blockade David L. Rimm MD-PhD Professor Departments of Pathology and Medicine (Oncology) Director, Yale Pathology Tissue Services Disclosures
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Circulating Tumor DNA Management of Non-Small-Cell Lung Cancer (Liquid Biopsy) Page 1 of 36 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Circulating Tumor DNA
More informationClinical utility of precision medicine in oncology
Clinical utility of precision medicine in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900
More informationThe Pathology of Neoplasia Part II
The Pathology of Neoplasia Part II February 2018 PAUL BOGNER, MD A S S O C I A T E P R O F E S S O R O F O N C O L O G Y P A T H O L O G Y A N D D E R M A T O L O G Y Clinical goals of cancer pathology
More informationNext generation diagnostics Bringing high-throughput sequencing into clinical application
Next generation diagnostics Bringing high-throughput sequencing into clinical application Leonardo A. Meza-Zepeda, PhD Translational Genomics Group Institute for Cancer Research Leonardo.Meza-Zepeda@rr-research.no
More informationpatients in the era of
Communicating with cancer patients in the era of personalized medicine September 9 th, 2017 Gerald Prager, M.D. Comprehensive Cancer Center Vienna Medical University of Vienna, Austria Gerald Prager, M.D.
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationCharacterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser
Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why
More informationAVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB
Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits Next-generation performance in liquid biopsies 2 Accelerating clinical research From liquid biopsy to next-generation
More informationNon-Profit Startup Paradigm Launches Cancer Panel Based on DNA, RNA Sequencing
Non-Profit Startup Paradigm Launches Cancer Panel Based on DNA, RNA Sequencing April 11, 2014 By Tony Fong Non-profit diagnostics outfit Paradigm last month joined a growing list of entrants in the clinical
More informationEXAMPLE. ratio (%) Contraindication for treatment with panitumumab or cetuximab
Dr Kate Goodhealth Goodhealth Medical Clinic 123 Address Road SUBURBTOWN NSW 2000 Referring Doctor Your ref Address Dr John Medico 123 Main Street, SUBURBTOWN NSW 2000 Phone 02 9999 9999 Requested 17 May
More informationNon-hormonal therapies in advanced breast cancer: new and emerging approaches
Non-hormonal therapies in advanced breast cancer: new and emerging approaches Outline Review goals of treatment Demystify chemotherapy decision making Look at the evidence for improvements over time Discuss
More informationNGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation
NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation Michael R. Rossi, PhD, FACMG Assistant Professor Division of Cancer Biology, Department of Radiation Oncology Department
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationGenomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France
Genomic tests to personalize therapy of metastatic breast cancers Fabrice ANDRE Gustave Roussy Villejuif, France Future application of genomics: Understand the biology at the individual scale Patients
More informationHOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY
HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY 7 TH Annual New York Lung Cancer Symposium Saturday, November 10, 2012 William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationDevelopment of Circulating Tumor DNA
Development of Circulating Tumor DNA Title of presentation Arial Bold 30pt in White Biomarkers Secondary title 22pt using Arial Next in White Generation Sequencing Brian Dougherty PhD, MBA Translational
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Oncofocus Patient Test Report Oncologica UK Ltd, Suite 15-16, The Science Village, Chesterford Research Park, Cambridge, CB10 1XL www.oncologica.com - Tel: +44 (0)1223 785327
More informationChemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer * Substances without published evidence based on at
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationEXAMPLE. - Potentially responsive to PI3K/mTOR and MEK combination therapy or mtor/mek and PKC combination therapy. ratio (%)
Dr Kate Goodhealth Goodhealth Medical Clinic 123 Address Road SUBURBTOWN NSW 2000 Melanie Citizen Referring Doctor Your ref Address Dr John Medico 123 Main Street, SUBURBTOWN NSW 2000 Phone 02 9999 9999
More informationPredictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities
Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Sujana Movva 1, Wenhsiang Wen 2, Wangjuh Chen 2, Sherri Z. Millis 2, Margaret von Mehren 1, Zoran
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationTransforming treatment and improving survival for ovarian cancer patients. March 25, 2012
Transforming treatment and improving survival for ovarian cancer patients March 25, 2012 Introduction to Clearity Foundation Clearity profiling panel Overview Interpretation of results utilizing the Diane
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationPROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions
PROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions Outline Prognostic and diagnostic value of pathologic and molecular alterations in prostate cancer Current status
More informationNGS Gateway Lab Services
TM NGS Gateway Lab Services Accelerating Precision Medicine Design a Complete Genomic Testing Portfolio with Turnkey Assays About NGS Gateway Lab Services TM Designed to provide a gateway to your own in-house
More informationDisclosure of Relevant Financial Relationships NON-SMALL CELL LUNG CANCER: 70% PRESENT IN ADVANCED STAGE
MORPHOLOGY AND MOLECULAR TESTING IN NON-SMALL CELL OF LUNG NEW FRONTIEIRS IN CYTOPATHOLOGY PRACTICE American Society for Cytopathology San Antonio, Texas Sunday March 5, 2017 Disclosure of Relevant Financial
More informationMET skipping mutation, EGFR
New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM
More informationDr. Pravin D. Potdar. M.Sc, Ph.D, D.M.L.T.,DHE, DMS
Molecular Profiling of Cancer Cells Strategies for Developing Biomarkers for Targeted Therapies of Cancer Dr. Pravin D. Potdar. M.Sc, Ph.D, D.M.L.T.,DHE, DMS Head, Department of Molecular Medicine and
More informationTargeted Cancer Therapies
Targeted Cancer Therapies Primary Care Training Programme 14 th February 2018 Sin Chong Lau Consultant in Medical Oncology Financial Disclosure Honoraria: Amgen, Pfizer, Roche, Sanofi, Servier Meetings:
More informationMEDICAL POLICY. SUBJECT: MOLECULAR PANEL TESTING OF CANCERS TO IDENTIFY TARGETED THERAPIES (Excluding NSCLC and CRC) EFFECTIVE DATE: 12/21/17
MEDICAL POLICY SUBJECT: MOLECULAR PANEL TESTING OF PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationbiomarker testing What you need to know about... LUNG CANCER TREATMENTS
LUNG CANCER TREATMENTS What you need to know about... biomarker testing Copyright 2018 LUNGevity Foundation All rights reserved. No part of this publication may be reproduced, distributed, or transmitted
More informationI. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
More informationAVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect
More informationTargeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationGenomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
More informationcontinuing education Non-small cell lung cancer: Molecular targets and emerging options for care Daniel Morgensztern, MD
continuing education educational objectives After participating in this activity, clinicians should be better able to Perform diagnostic/molecular testing (EGFR, KRAS, EML4-ALK) for NSCLC according to
More informationDesign of Clinical Trials with Molecularly Targeted Therapies. Gilberto Schwartsmann
Design of Clinical Trials with Molecularly Targeted Therapies Gilberto Schwartsmann What are the basics of clinical trial design? Presented By Jordan Berlin at 2016 ASCO Annual Meeting Advances in molecular
More informationPrior Authorization. Additional Information:
Genetic Testing for Cowden Syndrome - PTEN Gene MP9488 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below Pre and post-test genetic
More informationOncomine Focus assay panel and Oncomine Knowledgebase Reporter.
Oncomine Focus assay panel and Oncomine Knowledgebase Reporter. How it can help to identify relevant alteration and early phase trials. Dr Isabelle SOUBEYRAN Dr Emmanuel KHALIFA Molecular Pathology Unit
More informationDr C K Kwan. Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK
HA Convention 2013 Dr C K Kwan MBChB, FRCR, FHKCR, FHKAM, MPM, CPI, MAppMgt(Hlth) Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK To personalize cancer
More informationDrug Resistance in ALK- and ROS1-Rearranged Lung Cancers. Alice T. Shaw, MD PhD Director, Center for Thoracic Cancers September 16, 2017
Drug Resistance in ALK- and ROS1-Rearranged Lung Cancers Alice T. Shaw, MD PhD Director, Center for Thoracic Cancers September 16, 2017 ALK and ROS1 are Related Tyrosine Kinases, and Both are Targeted
More informationDENOMINATOR: Adult patients with metastatic colorectal cancer who have a RAS (KRAS or NRAS) gene mutation
Quality ID #452 (NQF 1860): Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) 4 with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies National Quality Strategy Domain:
More informationThe Center for PERSONALIZED DIAGNOSTICS
The Center for PERSONALIZED DIAGNOSTICS Precision Diagnostics for Personalized Medicine A joint initiative between The Department of Pathology and Laboratory Medicine & The Abramson Cancer Center The (CPD)
More informationIntegration of Genomics Into Clinical Pathways. Precision Medicine and Decision Support
Integration of Genomics Into Clinical Pathways Precision Medicine and Decision Support Faculty Andrew Hertler, MD, FACP Chief Medical Officer New Century Health Andrew Hertler, MD, FACP is employed by
More informationLUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
More informationENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones
ENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid Vall d Hebron Institute of Oncology (VHIO), Barcelona Triple Negative
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More information5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff
5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff National molecular screening of patients with lung cancer for a national trial of multiple novel agents. 2000 NSCLC patients/year (late
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Panel Testing of Cancers to Identify Targeted Therapies File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_panel_testing_of_cancers_to_identify_targeted_therapies
More informationFluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS
APPLICATION NOTE Fluxion Biosciences and Swift Biosciences OVERVIEW This application note describes a robust method for detecting somatic mutations from liquid biopsy samples by combining circulating tumor
More informationClinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D.
Clinical Biomarker in Kidney Cancer Maria Nirvana Formiga, M.D., Ph.D. Disclosures I am on the Speaker s Bureau with Pfizer and Bayer Clinical trials of BMS and Pfizer Kidney Cancer 70% new cases in developed
More informationTARGETED THERAPY FOR LUNG CANCER. Patient and Caregiver Guide
TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Why Targeted Therapy?...2 Lung Cancer Basics...2 Changes in
More informationPersonalized Therapies for Lung Cancer. Questions & Answers
Personalized Therapies for Lung Cancer Questions & Answers What are Personalized Therapies for lung cancer? Like people, no two lung cancer tumors are the same. Personalized medicine (also known as precision
More informationPatient's Cancer Genomic Landscape
Patient Name/DOB: John Doe 3/10/1960 Ordering Physician: James Smith M.D. Ordering Location: University of Michigan 123 Medical Center Drive Ann Arbor MI 49221 Test Name: Paradigm Cancer Diagnostic (PCDx)
More informationRECENT ADVANCES IN THE MOLECULAR DIAGNOSIS OF BREAST CANCER
Technology Transfer in Diagnostic Pathology. 6th Central European Regional Meeting. Cytopathology. Balatonfüred, Hungary, April 7-9, 2011. RECENT ADVANCES IN THE MOLECULAR DIAGNOSIS OF BREAST CANCER Philippe
More informationTumor monitoring in a drop of blood.
Tumor monitoring in a drop of blood. PRECISION MEDICINE STARTS WITH A FINGER STICK. circulogene.com Circulogene Theranostics solution to liquid biopsy. Novel cell-free DNA enrichment method for high quantity
More informationInternational Course on Theranostics and Molecular Radiotherapy ImmunoPET in Breast Cancer
International Course on Theranostics and Molecular Radiotherapy ImmunoPET in Breast Cancer Geraldine Gebhart Jules Bordet Institute 5/10/2017 PLAN OF THE TALK Increasing role of antibodies in anti-cancer
More informationFrequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R
Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB
More information